HCV infection and non-Hodgkin lymphomas: an evolving story

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Hepatitis C virus (HCV) infection is a global health issue affecting 3% of the world's population.
• Epidemiological studies link HCV infection to an increased risk of B cell non-Hodgkin lymphomas (NHL).
• Geographic variability exists in the incidence of HCV-associated lymphomas.

Purpose of the Study:

• To explore the causal role of HCV in B cell non-Hodgkin lymphoma development.
• To review the efficacy of antiviral therapy in treating HCV-associated lymphomas.
• To discuss the implications of direct-acting antiviral agents in managing these conditions.

Main Methods:

• Review of epidemiological studies and clinical observations.
• Analysis of the impact of HCV eradication on lymphoma response.
• Evaluation of current and emerging antiviral treatment strategies.

Main Results:

• HCV eradication through antiviral treatment is associated with lymphoma response, strongly suggesting a causal relationship.
• Chronic antigenic stimulation driven by HCV is considered a primary factor in lymphoma development.
• Antiviral therapy is recommended for asymptomatic, indolent B cell lymphomas.

Conclusions:

• HCV eradication is a viable strategy for managing certain B cell lymphomas.
• Direct-acting antiviral agents offer a favorable profile for HCV eradication in HCV-positive diffuse large B cell lymphoma.
• Further research is needed on the optimal timing of antivirals for aggressive lymphomas, with multidisciplinary management recommended.